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versus calcimimetic, will not directly test 
the scientific question at hand. These issues 
will be particularly relevant if the Evalua-
tion of Cinacalcet Therapy to Lower Car-
diovascular Events trial demonstrates an 
effect of cinacalcet on mortality.10
Finally, RCTs are expensive. The design 
issues outlined above are subtle and com-
plex, with potential for conflicts between 
patient benefits and corporate marketing 
strategies. Public funding will be required 
to ensure that trial results maximally 
benefit patients.
Diverse and creative research by the 
nephrology community has generated 
renewed interest in vitamin D. We are cur-
rently challenged with the task of trans-
lating exciting discovery into improved 
clinical care for our patients. Pharmaco-
epidemiology studies have added critical 
data regarding the potential beneficial 
effects of vitamin D therapy in CKD. A large 
RCT is now needed to test the hypothesis 
that vitamin D therapy improves clinical 
outcomes in patients with kidney disease.
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The hunt for the perfect biomarker 
for acute kidney injury:  
back to gamma-trace?
Josephine P. Briggs1
The hunt for a good biomarker for acute kidney injury (AKI) is currently hot. 
It has recently been the subject of several excellent reviews1–3 and a useful 
meta-analysis,4 and we are hearing exhortations that this hunt should 
get high priority.3,5 The ideal marker (or set of markers) should facilitate 
early identification, stratify risk, and contribute to informative diagnostic 
classification. Perhaps most importantly, a good marker should aid the 
testing of interventions to prevent development of AKI and improve 
management. So, there are very good reasons to get on with it!
Kidney International (2008) 74, 987–989. doi:10.1038/ki.2008.426
While the practical arguments are per-
suasive, a secondary benefit of acute 
kidney injury (AKI) biomarker research 
will also be new basic understanding. An 
intriguing example is the recent paper by 
Ichimura and co-workers on KIM-1, one 
of the current candidate AKI biomark-
ers.6 In a study published in May 2008 in 
the Journal of Clinical Investigation, these 
investigators show that injured proximal 
tubule cells develop phagocytic capacity 
and become macrophage-like in their 
behavior. KIM-1, an epithelial cell surface 
protein upregulated by injury and shed 
into the urine by damaged cells, appears 
to play a causal role in this transforma-
tion. The finding that epithelial cells can 
acquire a phagocytic phenotype is unex-
pected and potentially important for tis-
sue repair and recovery.
In this issue of Kidney International, 
Koyner and co-workers7 report data on 
another current candidate, urinary cysta-
tin C. This study also raises biological 
questions and reminds us that that there 
are important unanswered questions 
about the renal biology of cystatin C. 
Cystatin C has a curious history. Serum 
cystatin C is getting all the attention these 
days for its potential utility for the esti-
mation of glomerular filtration rate. But 
cystatin C was actually first identified not 
as a serum marker but as a urinary marker. 
In 1961 Frederick Flynn, a clinical pathol-
ogist at University College Hospital, and 
Elizabeth Butler, a nurse at the same insti-
tution, reported a novel protein in urine 
of patients with proteinuria, which they 
called post-gamma protein because of its 
position after γ-globulins on an electro-
phoretic gel.8 In the ‘biomarker’ literature 
of that period, gamma-trace, as it came 
to be called, was placed in the group of 
low–molecular weight proteins associated 
with ‘tubular’ injury, hence part of ‘tubu-
lar’ proteinuria. Flynn and Platt argued 
that the presence of small proteins such as 
gamma-trace in urine reflected a failure of 
proximal reabsorption of freely filterable 
proteins,9 a question still of interest and 
still in need of further study.
The next chapter in the gamma-trace/
cystatin C story takes place in Sweden 
about 20 years later. The key investiga-
tors were two clinical pathologists at the 
University of Lund in Sweden, Anders 
Grubb and Helge Löfberg. They pursued 
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the gamma-trace protein, isolating it from 
human urine, developing an antibody and 
an immunoassay,10 and eventually deter-
mining its amino acid sequence.11 They 
established that its biochemical activ-
ity was that of a cystatin—that is, that it 
inhibited cysteine proteases—and they 
suggested that the name ‘gamma-trace’ 
should be abandoned and that it should be 
called cystatin C, as the third member of 
the cystatin family.12 They observed that it 
was abundant in urine of proteinuric sub-
jects but present only at very low levels in 
normal urine. They also were the first to 
note that levels were markedly elevated in 
the serum of people with failing kidneys, 
and they concluded that cystatin C was 
catabolized only by the kidney,10 another 
issue that needs further study.
The present study by Koyner and co-
workers7 is another chapter in the story of 
the gamma-trace protein or urinary cysta-
tin C. It continues a line of investigation 
pioneered by Herget-Rosenthal and collab-
orators, who solved some methodological 
problems in the measurement of urinary 
cystatin C and observed, in a rather hetero-
geneous sample of patients, that it showed 
promise as an AKI biomarker.13,14 Koyner 
et al.7 studied 72 adults undergoing cardiac 
surgery, measuring four of the current can-
didate markers prospectively at frequent 
intervals in the postsurgical period: serum 
cystatin C, urinary cystatin C, plasma 
neutrophil gelatinase-associated lipoca-
lin (NGAL), and urinary NGAL. Their 
results suggest that, in this setting, of the 
four markers examined, urinary cystatin C 
is the most promising predictive marker. 
The study is of clear interest and should 
stimulate further work.
Nonetheless, there are a few pertinent 
cautions about this study. The authors 
defined risk of AKI rather liberally, requir-
ing only a 25% increase in serum creati-
nine, not the 50% increment or increase of 
0.3 mg/dl suggested by the RIFLE criteria;2 
very few of their patients required renal 
replacement therapy. It is quite possible 
that the apparent good specificity of uri-
nary cystatin C will disappear when it is 
studied in a population with higher rates 
of severe injury. Furthermore, the poor 
performance of serum markers in this 
population almost certainly reflects in 
part the postoperative hemodilution seen 
after cardiac surgery. Finally, the relatively 
weak performance of plasma NGAL in 
this study is not consistent with an earlier 
study by Mishra and co-workers,15 per-
haps because of technical differences in 
the measurement technique.
In spite of these cautions, I think we can 
be encouraged that progress is being made 
in the AKI biomarker hunt. Certainly uri-
nary markers look particularly informa-
tive, and it looks likely that the hunt for 
the AKI biomarker will also capture better 
biological understanding of renal injury. 
We can expect, I believe, to learn interest-
ing biological lessons from the variations 
in ‘tubular’ urinary proteins (Figure 1). 
There are some good questions ahead. 
How does the kidney handle cystatin C 
normally? Is it correct that the presence of 
a small protein such as cystatin C in urine 
reflects failed proximal reabsorption? Are 
the implications of this marker different 
from those of a marker such as KIM-1, 
probably derived from damaged epithelial 
cells and upregulated by injury?
So stay tuned to the AKI biomar-
ker hunt! The practical applications 
remain pressing, and the biology looks 
very interesting.
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Preservation of the kidney  
by carbon monoxide:  
a black swan phenomenon
Karl A. Nath1
Nakao and colleagues demonstrate that carbon monoxide added to 
organ preservation solution reduces donor-kidney injury that occurs 
after cold storage and transplantation and improves the survival of the 
recipient. These findings are important because they highlight the role of 
the cytochrome P450 system in the pathogenesis of donor-kidney injury 
and they suggest a strategy for preserving the donor kidney, namely, the 
addition of carbon monoxide to organ preservation solution.
Kidney International (2008) 74, 989–991. doi:10.1038/ki.2008.423
Carbon monoxide (CO) possesses a high 
affinity for the heme prosthetic group, the 
latter representing a defining motif for a 
family of ubiquitous and functionally 
diverse proteins. Such binding may mark-
edly impair the function of these proteins, 
and for heme proteins that subserve a vital 
function, the consequences can be lethal. 
For example, the affinity of CO for hemo-
globin is more than 200 times greater than 
that of oxygen, and in sufficiently high 
concentrations, CO vitiates the oxygen-
carrying capability of hemoglobin and 
thereby compromises the oxygenation of 
tissues. Through these and other effects, 
CO can cause acute and chronic toxicity, 
and, indeed, environmental exposure to 
CO is one of the commonest causes of 
accidental poisoning in the United States, 
and a cause for considerable and appro-
priate public concern.
Viewed from this perspective, it may 
come as a surprise that CO added to 
organ preservation solution can improve 
the function of the transplanted kidney 
and the survival of the recipient. Yet these 
remarkable findings are described in an 
important study by Nakao et al.1 (this 
issue). In addition to suggesting a strategy 
for organ preservation, these findings of 
Nakao et al.1 are a significant step in the 
steady procession of experimental studies 
demonstrating the remarkable cytoprotec-
tive properties of CO when it is present 
in relatively low concentrations.2–4 The 
initial demonstration that induction of 
heme oxygenase-1 (HO-1) can confer a 
protective response against tissue injury 
stimulated interest in HO-1 as a cytopro-
tective molecule, and in identification of 
the specific HO product and downstream 
effect of the induction of HO-1 that are 
responsible for such cytoprotection.5 
Initially, attention was directed to the 
synthesis of ferritin (an antioxidant, iron-
binding protein) and the production of 
bile pigments (antioxidant metabolites) 
as potential mechanisms.5 CO, the other 
main product of HO activity, while rec-
ognized as a vasorelaxant molecule and 
incriminated as a signaling species, was 
not considered, at the time, a cytopro-
tective molecule. This salutary property 
of CO was shown in 1999 in a landmark 
study that demonstrated that CO, at rela-
tively low concentrations (50–500 parts 
per million), protected against hyperox-
ia-induced lung injury by suppressing 
inflammation and apoptosis.6 These find-
ings presaged a groundswell of investiga-
tions demonstrating the beneficial effects 
of CO (when present in such low concen-
trations) in diverse models of tissue injury, 
and which reflected, depending on the dis-
ease model, any one or combination of the 
following properties of CO: antiapoptotic, 
anti-inflammatory, immune-suppressant, 
antithrombotic, angiogenic, antifibrotic, 
and vasorelaxant.2–4,7,8 Moreover, such 
protection was conferred not only by CO 
administered as a gas but also by novel 
CO-releasing compounds.3
The cytoprotective properties of HO-1 
were rapidly explored in the field of trans-
plantation and were observed to mitigate 
ischemia/reperfusion injury of the trans-
planted kidney, acute renal allograft rejec-
tion, and chronic allograft nephropathy; 
these protective effects were recapitulated, 
in part, by products of HO such as CO 
and/or bile pigments.7,8 Attention was 
also directed to organ preservation, an 
issue of central importance in this field, 
and one renewed by the increasing use of 
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